HK1123554A1 - Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists - Google Patents

Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists

Info

Publication number
HK1123554A1
HK1123554A1 HK09101245.2A HK09101245A HK1123554A1 HK 1123554 A1 HK1123554 A1 HK 1123554A1 HK 09101245 A HK09101245 A HK 09101245A HK 1123554 A1 HK1123554 A1 HK 1123554A1
Authority
HK
Hong Kong
Prior art keywords
indol
spiro
carbonyl
receptor antagonists
piperidine derivatives
Prior art date
Application number
HK09101245.2A
Other languages
English (en)
Inventor
Caterina Bissantz
Christophe Grundschober
Hasane Ratni
Mark Rogers-Evans
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1123554A1 publication Critical patent/HK1123554A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK09101245.2A 2005-07-14 2009-02-11 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists HK1123554A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05106443 2005-07-14
EP05109364 2005-10-07
PCT/EP2006/063846 WO2007006688A1 (en) 2005-07-14 2006-07-04 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists

Publications (1)

Publication Number Publication Date
HK1123554A1 true HK1123554A1 (en) 2009-06-19

Family

ID=37001896

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09101245.2A HK1123554A1 (en) 2005-07-14 2009-02-11 Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists

Country Status (26)

Country Link
US (2) US7332501B2 (de)
EP (1) EP1904477B1 (de)
JP (1) JP4927079B2 (de)
KR (1) KR100974967B1 (de)
CN (1) CN101253164B (de)
AR (1) AR054830A1 (de)
AT (1) ATE421511T1 (de)
AU (1) AU2006268724B2 (de)
BR (1) BRPI0612988A2 (de)
CA (1) CA2615726C (de)
CY (1) CY1108996T1 (de)
DE (1) DE602006004997D1 (de)
DK (1) DK1904477T3 (de)
ES (1) ES2317558T3 (de)
HK (1) HK1123554A1 (de)
IL (1) IL188478A (de)
MX (1) MX2008000585A (de)
MY (1) MY144684A (de)
NO (1) NO20080059L (de)
PL (1) PL1904477T3 (de)
PT (1) PT1904477E (de)
RU (1) RU2414466C2 (de)
SI (1) SI1904477T1 (de)
TW (1) TWI312780B (de)
WO (1) WO2007006688A1 (de)
ZA (1) ZA200800320B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0612988A2 (pt) * 2005-07-14 2010-12-14 Hoffmann La Roche derivados de indol-3-il-carbonil-espiro-piperidina como antagonistas de receptor v1a
CA2623715A1 (en) * 2005-09-28 2007-04-12 F. Hoffmann-La Roche Ag Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
CN101547923A (zh) * 2006-12-07 2009-09-30 弗·哈夫曼-拉罗切有限公司 作为via受体拮抗剂的螺环-哌啶衍生物
ES2345132T3 (es) 2006-12-08 2010-09-15 F. Hoffmann-La Roche Ag Indoles que actuan como agonistas del receptor v1a.
WO2008077810A2 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
ATE536356T1 (de) 2007-01-12 2011-12-15 Hoffmann La Roche Spiropiperidin-glycinamid-derivate
TW200940547A (en) * 2007-12-13 2009-10-01 Speedel Experimenta Ag Organic compounds
WO2011137024A1 (en) * 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
SI2683723T1 (sl) 2011-03-10 2016-07-29 Zoetis Services Llc Spirociklični izoksazolinski derivati kot antiparazitiki
RU2475489C1 (ru) * 2011-10-07 2013-02-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Чувашский государственный университет имени И.Н. Ульянова" Способ получения 8-амино-1-имино-6-морфолин-4-ил-2-окса-7-азаспиро[4,4]нона-3,6,8-триен-9-карбонитрилов
SI2825542T1 (sl) 2012-03-16 2017-01-31 Vitae Pharmaceutical Inc., Modulatorji jetrnega receptorja X
PL2825541T3 (pl) 2012-03-16 2016-12-30 Modulatory receptora x wątroby
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
KR101698124B1 (ko) * 2015-05-29 2017-01-19 한국외국어대학교 연구산학협력단 3-(메틸아미노)-3-((r)-피롤리딘-3-일)프로판니트릴 또는 이의 염의 제조방법
WO2017137334A1 (en) * 2016-02-08 2017-08-17 F. Hoffmann-La Roche Ag Spiroindolinones as ddr1 inhibitors
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
RU2752088C1 (ru) * 2016-09-21 2021-07-22 Вектус Байосистемс Лимитед Композиции для лечения гипертензии и/или фиброза
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
CN113563255B (zh) * 2020-04-29 2023-08-18 成都倍特药业股份有限公司 瑞芬沙星中间体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
EP1410437A2 (de) * 2001-01-22 2004-04-21 Morgan Chemical Products, Inc. Cvd-diamant verbessertes mikroprozessor-kühlsystem
BRPI0612988A2 (pt) * 2005-07-14 2010-12-14 Hoffmann La Roche derivados de indol-3-il-carbonil-espiro-piperidina como antagonistas de receptor v1a

Also Published As

Publication number Publication date
CN101253164B (zh) 2012-05-16
TWI312780B (en) 2009-08-01
AU2006268724A1 (en) 2007-01-18
JP4927079B2 (ja) 2012-05-09
KR20080024231A (ko) 2008-03-17
US20070027173A1 (en) 2007-02-01
NO20080059L (no) 2008-04-02
ATE421511T1 (de) 2009-02-15
ZA200800320B (en) 2009-02-25
CA2615726C (en) 2014-05-27
AU2006268724B2 (en) 2011-06-02
US7332501B2 (en) 2008-02-19
DE602006004997D1 (de) 2009-03-12
IL188478A0 (en) 2008-04-13
EP1904477B1 (de) 2009-01-21
WO2007006688A1 (en) 2007-01-18
CY1108996T1 (el) 2014-07-02
IL188478A (en) 2012-01-31
US20080146557A1 (en) 2008-06-19
RU2008100082A (ru) 2009-08-20
BRPI0612988A2 (pt) 2010-12-14
CN101253164A (zh) 2008-08-27
US7629353B2 (en) 2009-12-08
JP2009501185A (ja) 2009-01-15
PL1904477T3 (pl) 2009-07-31
CA2615726A1 (en) 2007-01-18
SI1904477T1 (sl) 2009-06-30
TW200726469A (en) 2007-07-16
PT1904477E (pt) 2009-03-12
KR100974967B1 (ko) 2010-08-09
DK1904477T3 (da) 2009-03-16
RU2414466C2 (ru) 2011-03-20
MX2008000585A (es) 2008-03-14
ES2317558T3 (es) 2009-04-16
MY144684A (en) 2011-10-31
AR054830A1 (es) 2007-07-18
EP1904477A1 (de) 2008-04-02

Similar Documents

Publication Publication Date Title
IL188478A0 (en) Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
ZA200800353B (en) Pyrazine derivatives useful as adenosine receptor antagonists
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
ZA200708028B (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists
GB0509275D0 (en) Synthetic receptor
EP2058304A4 (de) P2x4-rezeptorantagonist
IL184816A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
AP2007004047A0 (en) Substituted triazole derivatives as oxtocin antagonists
AP2008004441A0 (en) Piperdin-4-ylpyrazin-2-ylamine derivatives as fastdissociating dopamine 2 receptor antagonists
IL186188A0 (en) Pyrimidindione derivatives as prokineticin 2 receptor antagonists
AP1983A (en) Carboxamide derivatives as muscarinic receptor antagonists
IL190152A0 (en) Indane derivatives as mch receptor antagonists
IL192308A0 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
GB0509276D0 (en) Synthetic receptor
HU0501169D0 (en) New phenantridine derivatives as selective bradykinin b1 receptor antagonists
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
ZA200903496B (en) Spiro-piperidine derivatives as via receptor antagonists
GB0525029D0 (en) Receptor Antagonist
ZA200800516B (en) Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as V1a receptor antagonists
GB0516946D0 (en) Receptor
GB0516617D0 (en) EP2 Receptor antagonists
GB0522484D0 (en) Receptor
GB0510253D0 (en) Receptor
GB0522077D0 (en) Receptor

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180704